The Top Penny Stocks newsletter for active penny stocks investors looking for penny stocks and pink sheet stocks
Richemont chairman Johann Rupert to take 'grey gap... Billionaire 62-year-old to take 12 months off from Cartier and Montblanc luxury goods groupRichemont's chairman and founder Johann Rupert is to take a year off from September, leaving management of the...
Cambodia: aftermath of fatal shoe factory collapse... Workers clear rubble following the collapse of a shoe factory in Kampong Speu, Cambodia, on Thursday
Spate of recent shock departures by 50-something CEOs While the rising financial rewards of running a modern multinational have been well publicised, executive recruiters say the pressures of the job have also been ratcheted upOn approaching his 60th birthday...
UK Uncut loses legal challenge over Goldman Sachs tax... While judge agreed the deal was 'not a glorious episode in the history of the Revenue', he ruled it was not unlawfulCampaign group UK Uncut Legal Action has lost its high court challenge over the legality...
Eurozone crisis live: Japan's strong growth figures... PM Shinzo Abe's stimulus package could generate feelgood factor needed to end two decades of stagnant growthPhillip Inman
SOUTH SAN FRANCISCO, Calif. (TheStreet) — U.S. regulators have approved Onyx Pharmaceuticals’ multiple myeloma drug Kyprolis.
Onyx shares rose 12% to $76.47 in late Friday trading.
Kyprolis will be used to treat patients with multiple myeloma that is no longer responding to other therapies, including Celgene’s Revlimid or Thalomid and Takeda’s Velcade. …
Click to view a price quote on ONXX.
Click to research the Drugs industry.
More here: Onyx’s Kyprolis Cancer Drug Approved
Category : Stocks, World News
Celgene (CELG) is one of two firms other than GSK that are considering buying Human Genome (HGSI) and are holding talks with the company, Reuters reports. There’s no word on who the second suitor is, although any deal would most likely be a merger of equals. With Human Genome holding an auction, the deadline for bids is July 16. 
Post your comment!
Category : Stocks
Onyx Pharma FDA Panel Live Blog
WASHINGTON, D.C. (TheStreet) –Onyx Pharmaceuticals brings its multiple myeloma drug carfilzomib in front of a panel of outside experts convened by the U.S. Food and Drug Administration.
The experts on Wednesday afternoon’s panel will review clinical data on carfilzomib as a treatment for advanced multiple myeloma patients who are no longer responding to currently approved medicines. The FDA is asking the panel to vote on whether or not to recommend the approval of carfilzomib. …
Click to view a price quote on ONXX.
Click to research the Drugs industry.
Go here to see the original: Onyx Pharma: FDA Panel Live Blog
Category : Business
ASCO 2012 Live Blog – Sunday
CHICAGO (TheStreet) –Welcome to TheStreet’s live-blog coverage of the American Society of Clinical Oncology (ASCO) annual meeting. It’s Sunday, the second full day of data presentations at the largest annual gathering of cancer drug researchers in the world.
On the schedule for today: ASCO’s big plenary session, highlighting some of the most newsworthy clinical data at the conference. Roche and ImmunoGen are in the plenary spotlight this year with data from the phase III study of T-DM1 in breast cancer. Also sharing the plenary stage is a study combining Roche’s Rituxan with Teva’s Treanda in lymphoma. …
Click to view a price quote on RHHBY.
See the article here: ASCO 2012 Live Blog — Sunday
Search Jim Cramer’s “Mad Money” trading recommendations using our exclusive “Mad Money” Stock Screener and watch Jim Cramer’s “Mad Money” Post Game video exclusively on TheStreet.com.
NEW YORK (TheStreet) — Investors rejoice but traders beware. Those were Jim Cramer’s words to his “Mad Money” TV show viewers Friday, as he laid out his game plan for next week’s trading. He explained that Friday’s unemployment data could wipe out any gains for the week, but that will only give longer-term investors a chance to buy on the cheap.
…
Click to view a price quote on AIG.
Click to research the Insurance industry.See the article here: Cramer’s ‘Mad Money’ Recap: Game Plan for Next Week (Final)
Category : Business
Updated with new stock price.
SOUTH SAN FRANCISCO, Calif. (TheStreet) — Treatment with Threshold Pharmaceuticals’ TH-302 helped patients with advanced pancreatic cancer extended by two months the time before their disease worsened, according to results of a phase II study released Monday.
Shares of Threshold were up 65% to $5.82 in Tuesday trading.
…
Click to view a price quote on THLD.
Click to research the Drugs industry.Read more: Threshold Drug Delays Pancreatic Cancer